• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Lawrence N. Shulman, MD


  • Shulman LN.The effect of accountable care organizations on oncology practice.Am Soc Clin Oncol Educ Book. 2014;34:e468-71.
  • Shulman LN, Mamon H, Jacobson JO, Steingisser L, Dodek A, Fallon JA.Partnership between a cancer center and payer: opportunities for improved quality of care and cost reduction.J Oncol Pract. 2013 May;9(3):133-4.
  • Sharma K, Costas A, Damuse R, Hamiltong-Pierre J, Pyda J, Ong CT, Shulman LN, Meara JG.The Haiti Breast Cancer Initiative: Initial Findings and Analysis of Barriers-to-Care Delaying Patient Presentation.J Oncol. 2013;2013:206367.
  • Silva TB, Mauad EC, Carvalho AL, Jacobs LA, Shulman LN.Difficulties in implementing an organized screening program for breast cancer in Brazil with emphasis on diagnostic methods.Rural Remote Health. 2013;13:2321.
  • Weingart SN, Mattsson T, Zhu J, Shulman LN, Hassett M.Improving electronic oral chemotherapy prescription: can we build a safer system?.J Oncol Pract. 2012 Nov;8(6):e168-73.
  • Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, , Cox NJ, Dolan ME.Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Clin Cancer Res. 2013 Jan 15;19(2):491-9.
  • Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ.Tumor boards and the quality of cancer care.Journal of the National Cancer Institute. 2013 Jan 16;105(2):113-21.
  • Weingart SN, Cleary A, Scullion B, Morway L, Phantumvanit V, Stuver SO, Shulman LN, Connors JM.Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology.J Oncol Pharm Pract. 2012 Nov 21.
  • Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C.Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101.J Clin Oncol. 2012 Nov 20;30(33):4071-6.
  • Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL.A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.Clin Cancer Res. 2012 Sep 15;18(18):5099-109.
  • Sharma K, Costas A, Shulman LN, Meara JG.A systematic review of barriers to breast cancer care in developing countries resulting in delayed patient presentation.J Oncol. 2012;2012:121873.
  • Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA.Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.Breast Cancer Res Treat. 2012 Jul;134(2):683-92.
  • Knaul FM, Shulman LN, Gralow J, Quick J, Bhadelia A, Frenk J.Improving pathology for better cancer care and control in countries of low and middle income.Lancet. 2012 Jun 2;379(9831):2052.
  • Bunnell CA, Weingart SN, Swanson S, Mamon HJ, Shulman LN.Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center.J Oncol Pract. 2010 Nov;6(6):283-8.
  • Bunnell CA, Shulman LN.Will we be able to care for cancer patients in the future?.Oncology (Huntingt). 2010 Dec;24(14):1343-8. Review.
  • Shulman LN, Willett W, Sievers A, Knaul FM.Breast cancer in developing countries: opportunities for improved survival.J Oncol. 2010;2010:595167.
  • Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR.Expansion of cancer care and control in countries of low and middle income: a call to action.Lancet. 2010 Oct 2;376(9747):1186-93. Review.
  • Drews RE, Shulman LN.Update in hematology and oncology.Ann Intern Med. 2010 May 18;152(10):655-62. Review.
  • Weingart SN, Toro J, Spencer J, Duncombe D, Gross A, Bartel S, Miransky J, Partridge A, Shulman LN, Connor M.Medication errors involving oral chemotherapy.Cancer. 2010 May 15;116(10):2455-64.
  • Carlson JW, Lyon E, Walton D, Foo WC, Sievers AC, Shulman LN, Farmer P, Nosé V, Milner DA.Partners in pathology: a collaborative model to bring pathology to resource poor settings.Am J Surg Pathol. 2010 Jan;34(1):118-23.
  • Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R.Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.Clin Cancer Res. 2009 Dec 15;15(24):7693-7700.
  • Weingart SN,Saadeh MG,Simchowitz B,Gandhi TK,Nekhlyudov L,Studdert DM,Puopolo AL,Shulman LN.Process of care failures in breast cancer diagnosis.J Gen Intern Med. 2009 Jun;24(6):702-9.
  • Ettinger DS,Agulnik M,Cristea M,Eaton K,Fidias PM,Gockerman JP,Hameed O,Handorf C,Harris EI,Jacobs CD,Javle M,Khushalani NI,Kvols L,Lenzi R,Lewis NL,Rashid A,Saltz L,Shulman LN,Zager JS,Zhen W.Occult primary.J Natl Compr Canc Netw. 2008 Nov;6(10):1026-60. Review.
  • Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP.VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.Clin Cancer Res. 2008 Dec 1;14(23):7871-7.
  • Goldstein LJ,O'Neill A,Sparano JA,Perez EA,Shulman LN,Martino S,Davidson NE.Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.J Clin Oncol. 2008 Sep 1;26(25):4092-9.
  • Goldstein LJ,Gray R,Badve S,Childs BH,Yoshizawa C,Rowley S,Shak S,Baehner FL,Ravdin PM,Davidson NE,Sledge GW Jr,Perez EA,Shulman LN,Martino S,Sparano JA.Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.J Clin Oncol. 2008 Sep 1;26(25):4063-71.
  • Bansal A,Binkert CA,Robinson MK,Shulman LN,Pellerin L,Davison B.Impact of quality management monitoring and intervention on central venous catheter dysfunction in the outpatient chemotherapy infusion setting.J Vasc Interv Radiol. 2008 Aug;19(8):1171-5.
  • Shulman LN, Hitt RA, Ferry JA.Case records of the Massachusetts General Hospital. Case 4-2008. A 33-year-old pregnant woman with swelling of the left breast and shortness of breath.N Engl J Med. 2008 Jan 31;358(5):513-23.
  • Weingart SN, Cleary A, Seger A, Eng TK, Saadeh M, Gross A, Shulman LN.Medication reconciliation in ambulatory oncology.Jt Comm J Qual Patient Saf. 2007 Dec;33(12):750-7.
  • Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP.Sarcoidosis mimicking metastatic breast cancer.Clin Breast Cancer. 2007 Oct;7(10):804-10.
  • Cruz GD, Shulman LC, Kumar JV, Salazar CR.The cultural and social context of oral and pharyngeal cancer risk and control among Hispanics in New York.J Health Care Poor Underserved. 2007 Nov;18(4):833-46.
  • Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN.Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.Invest New Drugs. 2007 Aug;25(4):369-75.
  • Shulman L, Ost D.Advances in bronchoscopic diagnosis of lung cancer.Curr Opin Pulm Med. 2007 Jul;13(4):271-7. Review.
  • Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, Shulman LN, Connor M.Oral chemotherapy safety practices at US cancer centres: questionnaire survey.BMJ. 2007 Feb 24;334(7590):407.
  • Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A.Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.J Clin Oncol. 2005 Mar 20;23(9):1934-40.
  • McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS.Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.Am J Clin Oncol. 2004 Oct;27(5):485-8.
  • Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN.Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.Ann Oncol. 2003 Feb;14(2):268-72.
  • Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW.Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.J Clin Oncol. 2002 Sep 15;20(18):3772-84.
  • Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB.Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.J Clin Oncol. 2002 Mar 15;20(6):1562-9.
  • Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN.Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55.
  • Jacobson JO, Grossbard M, Shulman LN, Neuberg D.CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.Clin Lymphoma. 2000 Dec;1(3):211-7; discussion 218.
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2001 May 15;19(10):2722-30.
  • Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN.Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.Cancer. 2000 May 1;88(9):2037-41.
  • Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN.Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):349-53.
  • Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP.Docetaxel administered on a weekly basis for metastatic breast cancer.J Clin Oncol. 2000 Mar;18(6):1212-9.
  • Dubey A, Recht A, Come SE, Gelman RS, Silver B, Harris JR, Shulman LN.Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study.Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):877-84.
  • Shulman LN, Tarbell NJ, Storen E, Marcus K, Mauch PM.Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission.Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1113-7.
  • Smith D, Shaffer K, Kirn D, Canellos GP, Mauch PM, Shulman LN.Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment.Oncology. 1998 Jul-Aug;55(4):284-8.
  • Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW.Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.Clin Cancer Res. 1998 Feb;4(2):317-24.
  • Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL.Skin recurrences after breast-conserving therapy for early-stage breast cancer.J Clin Oncol. 1998 Feb;16(2):480-6.
  • Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN.A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.Cancer. 1998 Feb 1;82(3):561-6.
  • Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C.Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation.Blood. 1998 Jan 15;91(2):717-23.
  • Wong JS, Recht A, Beard CJ, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos TI, Nixon AJ, Shulman LN, Troyan S, Silver B, Harris JR.Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes.Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):915-20.
  • Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA.Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.J Clin Oncol. 1997 Apr;15(4):1631-7.
  • Shaffer K, Smith D, Kirn D, Kaplan W, Canellos G, Mauch P, Shulman LN.Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation.AJR Am J Roentgenol. 1996 Aug;167(2):425-30.
  • Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR.The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.N Engl J Med. 1996 May 23;334(21):1356-61.
  • Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN.High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.J Clin Oncol. 1995 Dec;13(12):2916-23.
  • Shulman LN, Buswell L, Goodman H, Muto M, Berkowitz R, Teicher B, Kusumoto T, Hurwitz SJ, Kalish LA, Coleman CN.Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer.Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):545-8.
  • Ballen KK, Gilliland DG, Kalish LA, Shulman LN.Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival.Cancer. 1994 Jan 15;73(2):314-21.
  • Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G.Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome.J Clin Oncol. 1993 May;11(5):937-42.